Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis

Yuegang Li1, Yuwei Du1, Chi Xue1, Pei Wu1, Nan Du1, Guolian Zhu2, Huimian Xu1 and Zhi Zhu1*

Abstract
Background: Immune checkpoint inhibitors have shown promise in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) advanced colorectal cancer (CRC) immunotherapy, and many clinical trials have been conducted.

Objective: To evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in advanced CRC.

Method: PubMed, Web of Science, Embase, and The Cochrane Library were searched for relevant studies up to September 2021. A retrospective cross-sectional data analysis was performed and Stata 16 software was used for analyses.

Results: Sixteen studies including 1503 patients were analyzed. The objective response rate (ORR) of anti-PD-1/PD-L1 was 23% (95% CI 0.14, 0.31); the overall 1-year survival rate (OSR) was 57% (95% CI 0.42, 0.73). The ORR of MSI-H/dMMR advanced CRC was 37% (95% CI 0.25, 0.48) and that of microsatellite stable/mismatch repair proficient (MSS/pMMR) disease was 11% (95% CI 0.06, 0.16). The ORR was 42% in the BRAF mutant subgroup and 19% in the RAS mutant group. The ORR was 14% in the PD-L1 (+) subgroup and 32% in the PD-L1(-) subgroup. The rate of adverse effects was 85% (95% CI 0.80, 0.91).

Conclusion: Anti-PD-1/PD-L1 therapy in MSI-H/dMMR advanced CRC was associated with improved survival. Anti-PD-1/PD-L1 combined with antiangiogenic drugs, targeted agents, or chemotherapy might be effective in MSS mCRC. Immunotherapy was effective for the BRAF mutant and KRAS/NRAS(RAS) mutant CRC. Low expression of PD-L1 was a potential predictive marker for positive response and outcome. The high incidence of adverse events at 85% was worthy of further investigation. Further analysis with a higher number of high-quality studies is needed to verify the conclusions.

Keywords: PD-1, PD-L1, Immunotherapy, Colorectal cancer, Meta-analysis

Background
Colorectal cancer (CRC) is the third most common cancer in the world and ranks second in mortality. Every year more than 800,000 people worldwide die from CRC [1]. The 5-year survival rate for patients with early CRC can reach 90% compared with 10% for metastatic CRC (mCRC) [2]. The standard chemotherapy for mCRC is fluoropyrimidine, oxaliplatin, and irinotecan-based combination regimens with anti-EGFR and anti-VEGF treatment [3–6]. This strategy has achieved positive short-term results, although the long-term efficacy is poor. Several recent studies show that the PD-1/PD-L1 pathway affects the balance between tumor immune escape and immune surveillance [7, 8]. Antibodies that block the PD-1/PD-L1 pathway have been
approved for multiple solid tumors, including melanoma [9], lung cancer [10], head and neck cancer [11], urothelial cancer [12], Merkel cell carcinoma [13], and microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) mCRC. ASCO released the results of the KEYNOTE-177 study in 2020, which indicated that patients randomly assigned to receive pembrolizumab had significantly better overall survival (OS) and safety than patients receiving continued standard chemotherapy [14]. Although immunotherapy has achieved a certain efficacy in patients with MSI-H/dMMR mCRC, this population of patients accounts for 5% of mCRC patients, whereas 95% of mCRC patients present with microsatellite stable (MSS) disease. The KEYNOTE016 study showed that single immunotherapy was not effective for MSS mCRC patients [15]. Combination strategies with immunotherapy and the identification of predictive biomarkers for immunotherapy in MSS mCRC have become the focus of intense research efforts. However, most global studies on immunotherapy-related treatments for mCRC patients are single-arm and small clinical trials. Here, we performed a search of the relevant literature and conducted a meta-analysis of the efficacy and safety of anti-PD-1/PD-L1 therapy.

Search strategy
We searched for eligible trials analyzing the use of anti-PD-1/PD-L1 therapy in the treatment of CRC published in PubMed, Web of Science, Embase, and The Cochrane Library from the date of their inception to Sep 1, 2021. The keywords used for the search were “colorectal neoplasms”, “colorectal cancer”, “colorectal tumors”, “colorectal carcinoma”, “immune checkpoint inhibitor”, “PD-1 Inhibitors”, “programmed cell death protein 1 inhibitor”, “PD-L1 Inhibitors”; and “Programmed Death-Ligand 1 Inhibitors”. We also searched the reference lists of retrieved articles to identify additional relevant publications.

Inclusion and exclusion criteria
We included all articles focusing on analyzing the use of anti-PD-1/PD-L1 therapy in the treatment of CRC. The inclusion criteria were as follows: studies investigating the efficacy of anti-PD-1/PD-L1 agents with or without anti-CTLA-4 in the treatment of advanced CRC; only original research published in English was considered. The exclusion criteria were as follows: studies published as reviews, letters, case reports, animal studies, and meeting abstracts; studies with incomplete or inaccurate data for analysis.

Data extraction
Two reviewers carried out the screening and extraction processes independently. Disagreements were resolved by discussion or by involving a third author. First, studies were screened by titles and abstracts. Then, the full text was read to determine whether it could be included. The data extracted included the following: (1) basic information of the study, including first author, publication year, country, study design, study interval, study objective, and sample size; (2) baseline characteristics of the research subjects, including the number of patients, age, the primary location and metastatic site of the tumor, microsatellite status, genotype, and PD-L1 status; and (3) outcome measures data. Results were checked by a third author.

Quality evaluation
The quality of the studies was assessed in accordance with the ROBINS-I tool for observational studies and ROBINS-2 tool for randomized trials. Risk of bias for each item was graded as “low risk was defined as comparable to a well performed randomized trial with regard to this domain,” “moderate risk was defined as sound for a non-randomized study with regard to this domain, but not comparable to a well-performed randomized trial,” “serious risk was defined as presence of some important problems,” and “critical risk was defined as too problematic to provide any useful evidence on the effects of intervention.”

Statistical analysis
The objective response rate (ORR), disease control rate (DCR), progression-free survival rate (PFSR), and the overall survival rate (OSR) with their 95% confidence intervals (CIs) were evaluated for the studies included in the meta-analysis. Heterogeneity in the outcomes was assessed using the $\chi^2$ and $I^2$ tests. $I^2 > 50\%$ and a $P$-value < 0.1 indicated significant heterogeneity, and the random-effects model was used. Otherwise, the fixed-effects model was used. Additional subgroup analysis was performed, and the results are described in detail. Funnel plots were generated to assess publication bias. All statistical analyses were performed using Stata16 software.

Results
Characteristics of studies
Sixteen studies including 1,503 patients were finally identified for inclusion into the study via full-text review and data extraction. The details of the selection process were in line with the PRISMA flowchart (Fig. 1). The characteristics of the 16 included studies are summarized in Table 1. Pie charts were drawn based on the primary tumor site and metastatic sites (Fig. 2A and B). The
quality of observational studies was evaluated using the ROBINS-I tool. The detailed information of each study is shown in Fig. 3. The RCT studies of André T using the ROBINS-2 tool was low risk of bias and the study by Chen was moderate risk of bias.

Meta-analysis

Efficacy [15–30]
The ORR of anti PD-1/PD-L1 therapy for advanced CRC was 23% [95%CI (0.14, 0.31) P < 0.001] (Fig. 4A). The DCR was 49% [95% CI (0.36, 0.62) P < 0.001] (Fig. 4B). The 1-year PFSR was 46% [95% CI (0.23, 0.68) P < 0.001] (Fig. 4C). The 1-year OSR was 57% [95% CI (0.42, 0.73) P < 0.001] (Fig. 4D). The median progression-free survival (mPFS) was 2.44 months [95% CI (2.16, 2.71), P < 0.001] (Fig. 4E).

Safety [15–30]
The incidence of any grade TRAEs associated with the treatment of advanced CRC with anti-PD-1/PD-L1 was 85% [95% CI (0.80, 0.91), P < 0.001] (Fig. 5A). The occurrence rate of grade 3 to 5 AEs was 33% [95% CI (0.25, 0.50), P < 0.001] (Fig. 5B). The most common AEs were diarrhea (36.0%), fatigue (32.82%), poor appetite (28.50%), nausea (25.10%), increased AST (22.46%), rash (22.37%), abdominal pain (20.60%), fever (19.88%), increased ALT (17.90%), hypothyroidism (12.62%), and pancreatitis (10.23%). Detailed descriptions of the adverse reactions are shown in Table 2.

Subgroup analysis

Microsatellite status [16–18, 23–25]
There were six studies analyzing microsatellite status. The ORR, DCR, and mPFS in MSI-H/dMMR patients
| Author/year | Case | Age  | Genotype (N) | Microsatellite instability status | PD-L1 expression | Intervention methods |
|-------------|------|------|--------------|-----------------------------------|------------------|---------------------|
|             |      |      | WT | BRAF | KRAS | Unknown | ≥ 1% | < 1% | Unknown |
| Overman (2018) | 119  | 58(21–88) | 31 | 29 | 44 | 15 | MSI–H 119 | 26 | 65 | 28 | Nivolumab (PD-1) + Ipilimumab (CTLA-4) |
| Overman (2017)  | 74   | 53(44-66) | 29 | 12 | 26 | 7 | MSI–H 74 | 21 | 47 | 6 | Nivolumab (PD-1) |
| Le D T (2019) | 124  | 56(21-84) | 17 | 14 | 46 | – | MSI–H 124 | – | – | – | Pembrolizumab (PD-1) |
| O’Neill (2017) | 23   | 57(40–78) | – | – | – | – | MSI–H 1 | 23 | – | – | Pembrolizumab (PD-1) |
| Le D T (2015) | 32   | 54(24–79) | – | 19 | 19 | – | MSI–H 11 | – | – | – | Pembrolizumab (PD-1) |
| André T (2020) | 307  | 63(24–93) | 69 | 77 | 74 | 90 | MSI–H 307 | – | – | – | Pembrolizumab (PD-1) |
| Fukuoka (2020) | 25   | 55(31–77) | – | – | 6 | – | MSI–H 3 | 9 | 16 | – | Pembrolizumab (PD-1) + Regorafenib |
| Herting (2020) | 30   | 49(28–74) | 21 | 0 | 14 | 26 | MSI–H 2 | – | – | – | Pembrolizumab (PD-1) + Modified FOLFOX6 |
| Kawazoe (2020) | 50   | 58(25–79) | 4 | 28 | 19 | 13 | MSI–H 10 | 4 | – | – | Pembrolizumab (PD-1) + Napabucasin™ |
| Eng C (2019) | 183  | 58 (51–67) | 258 | 9 | 99 | – | MSI–H 3 | 79 | 84 | 20 | Atezolizumab (PD-L1) + Cetuximab |
| Eng C (2019) | 90   | 56 (51–64) | 128 | 3 | 49 | – | MSI–H 3 | 35 | 42 | 13 | Atezolizumab (PD-L1) |
| Hellmann (2019) | 84   | 56(23–79) | 63 | 40 | 24 | 41 | MSI–H 12 | – | – | – | Atezolizumab (PD-L1) + Cetuximab |
| Patel (2021) | 18   | 56(40–70) | – | 1 | 12 | – | MSI 18 | – | – | – | Nivolumab (PD-1) + Regorafenib |
| Cousin (2021) | 48   | 62 (26–83) | – | 3 | 30 | – | MSI 48 | 6 | – | – | Aveluma (PD-L1) + Regorafenib |
| Chen (2020) | 180  | 65 (36–87) | – | – | – | – | MSI–H 2 | – | – | – | Durvalumab (PD-L1) + Pembrolizumab (CTLA-4) |
| Martinelli (2021) | 77   | – | 48 | 19 | 19 | 3 | MSI–H 3 | – | – | – | Atezolizumab (PD-L1) + Cetuximab |
| Wang (2021) | 39   | 52(37–69) | 13 | 2 | 20 | 4 | MSI 38 | – | – | – | Toripalimab (PD-1) + Regorafenib |

* VS Versus, WT wild type, MU mutant, MSI–H Microsatellite instability-high, MSS microsatellite-stable, MSI–L microsatellite instability-low
were 37%, 69%, and 10.06 months, respectively, whereas those in microsatellite stable/mismatch repair proficient (MSS/pMMR) patients were 10%, 57%, and 2.86 months, respectively (Fig. 6A–C). The results indicated that anti-PD-1/PD-L1 therapy was associated with clinical benefit in more than one-third of MSI-H/dMMR mCRC patients. The ORR of MSS patients who did not respond to previous single-drug treatment reached 10% after immunotherapy combined with other therapies.

Different genotypes [16–18, 24, 25, 29, 30]
Seven studies evaluated the ORR of patients with different genotypes. The ORR of the BRAF mutant subgroup, RAS mutant subgroup, and wild-type subgroup was 42%, 19%, and 25%, respectively (Fig. 7). The results indicated that immunotherapy was effective for BRAF mutant and KRAS/NRAS(RAS) mutant CRC, which may become a biomarker for the assessment of immunotherapy efficacy.
PD-L1 status [16, 18, 19, 21, 23, 24]
Six articles analyzed the effect of PD-L1 expression. In patients receiving anti-PD-1/PD-L1 therapy, the ORR of PD-L1(≥ 1%) patients was 14%, whereas that of the PD-L1(< 1%) subgroup was 32% (Fig. 8). PD-L1 expression was positively associated with decreased ORR.

Publication bias and influence analysis
Publication bias Funnel plots were used to investigate the potential publication bias of the studies included in the meta-analysis. As shown in Figs. 9 and 10, the funnel plots were asymmetric, suggesting a medium risk of publication bias because of insufficient RCT articles. In the MSI-H/dMMR subgroup, we performed an influence analysis. The results indicated that the data of O’Neil were the source of high heterogeneity in our meta-analysis, and when this study was removed, the heterogeneity of the remaining 10 studies decreased from 81.9 to 45.1% (Additional file 1). In the MSS subgroup, however, influence analysis showed that the study by Fukuoka had an effect on heterogeneity, so significantly reduced heterogeneity was found when ignoring the Fukuoka study (Additional file 2).
Fig. 5 Forest plots of any grade TRAEs (A) and grades ≥ 3 TRAEs (B)
Discussion
The KEYNOTE016 study of pembrolizumab monoclonal antibody therapy showed that the ORR of the MSI-H/dMMR CRC, MSI-H/dMMR nonCRC, and MSI-H/pMMR CRC subgroups was 40%, 71%, and 0%, respectively. This suggested that patients with advanced dMMR CRC benefited from PD-1 inhibitor therapy, whereas patients with pMMR CRC did not benefit from anti-PD-1 therapy [31]. The 2018 ESMO meeting first reported that the ORR of MSI-H/dMMR CRC patients receiving first-line immunotherapy was 60% in the Checkmate 142 study. [16, 17], which indicated the probability of immunotherapy transition from third-line therapy to first-line therapy. This study was immediately followed by the KEYNOTE-177 study, in which patients were randomized to a pembrolizumab arm and standard first-line treatment group. This study further suggested that pembrolizumab improved survival significantly compared with standard chemotherapy [20].

In the present meta-analysis, the ORR of anti-PD-1/PD-L1 antibody therapy in the treatment of advanced CRC reached 23%. Subgroup analysis showed that the ORR of anti-PD-1/PD-L1 antibody therapy in the MSI-H/dMMR subgroup was 36%, whereas the ORR in the MSS/pMMR subgroup was 10%. This indicated that immunotherapy was emerging as the next frontier in the treatment of MSI-H/dMMR mCRC. Alternatively, combination treatment with immunotherapy agents and other methods is also promising for MSS/pMMR mCRC patients. Anti-angiogenic agents have shown a positive synergistic effect with immunotherapy by improving the tumor immune microenvironment, improving drug delivery, and facilitating immune cell responses [32]. The Japanese REGONIVO study showed an ORR of 33% in advanced CRC patients with MSS status who received nivolumab and regorafenib [21]. However, the North American REGNIVO Phase II study failed to replicate the Japanese results with an ORR of 7%. Because of its likely synergistic effect on the immune system, anti-EGFR/anti-PD1 combination treatment could be a promising therapeutic option for MSS mCRC patients. The AVETUXIRI study divided MSS mCRC patients into two groups receiving avelumab in combination with cetuximab. The results showed that the OS of the RAS WT and RAS MUT groups was 12.7 and 14.0 months, respectively [33]. Studies exploring the efficacy of immunotherapy in combination with MEK inhibitors or chemotherapy did not find a clear advantage in efficacy and safety compared with chemotherapy combined with targeted drugs in MSS tumors [22, 24]. The efficacy and safety of combination therapy require further exploration.

Identifying predictive biomarkers of the response to immunotherapy in mCRC is important. The CAVE study reported that cetuximab combined with avelumab achieved certain efficacy in wild-type RAS mCRC patients [34]. The present meta-analysis showed that the ORR of the BRAF mutant, RAS mutant, and wild-type subgroups was 42%, 19%, and 25%, respectively. Further studies are necessary to determine whether genotype status could be a predictive marker of a positive response. In addition, there is an ongoing debate about the prognostic role of PD-L1, with both favorable and unfavorable outcomes reported in various malignancies [35]. A meta-analysis by Cao et al. [36] showed that PD-L1 overexpression was associated with poor prognosis in patients with CRC. In this meta-analysis, the definition of positive

| TRAE Name   | Studies       | Grade1-2 Heterogeneity rate (95% CI) % | Grade ≥ 3 Heterogeneity rate (95% CI) % |
|-------------|---------------|----------------------------------------|----------------------------------------|
| Diarrhoea   | 15–21,23,24,26–28,30 | Random 28 (18, 38)                     | Random 4 (2, 6)                         |
| Rash        | 15–20,21,23,24,27,28,30 | Random 15 (9, 21)                     | Random 2 (1, 3)                         |
| Fatigue     | 15–20,21,23,24,26–28,30 | Random 26 (17, 35)                     | Random 4 (2, 6)                         |
| Nausea      | 15–20,23,24,26–28  | Random 21 (14, 28)                     | Random 1 (0, 2)                         |
| Poor appetite | 18–20,23,24,26–28,30   | Random 23 (14, 33)                     | Random 2 (0, 4)                         |
| Abdominal pain | 15,17,20,24,26,28,30  | Random 15 (8, 23)                     | Random 3 (1, 5)                         |
| Pyrexia     | 15–17,20,23,24,26,27,30 | Random 16 (11, 21)                     | Random 2 (0, 3)                         |
| Increased AST | 16,17,20,23,27,28   | Random 16 (5, 27)                     | Random 4 (2, 6)                         |
| Increased ALT | 15–17,20,27,28     | Random 12 (5, 19)                     | Random 3 (2, 5)                         |
| Hypothyroidism | 15–17,20,23,27,30   | Random 11 (7, 16)                     | Random 1 (—1, 2)                       |
| Pancreatitis | 13,14,16,17,24,25   | Random 7 (2, 12)                      | Random 5 (1, 9)                         |
expression of PD-L1 was PD-L1 expression ≥ 1% or a combined positive score (CPS) of ≥ 1. This meta-analysis showed that the ORR of immunotherapy was 14% in the PD-L1(+) and 32% in the PD-L1(-) subgroup. PD-L1 expression in CRC cells may be a predictive biomarker of response to immunotherapy. Previous research reported that PD-L1 was expressed in neoplastic cells (NCs) and tumor-infiltrating immune cells [37] and was associated with dMMR advanced CRC [38]. Therefore, it is important to clearly define PD-L1 expression levels according to tumor-infiltrating immune cells and tumor mismatch repair status.

Several biomarkers have been proposed and are currently being investigated. The Scoop study reported that patients with right-sided primary tumors had a higher ORR to anti-PD-1 treatment than those with left-sided primary tumors [23]. The right-sided colon was associated with a higher frequency of consensus molecular subtypes (CMS1) and greater infiltration of immune cells with high cytotoxicity than the left-sided colon [39], which might be one of the reasons for the different response to immunotherapy. The North American REGNIVO and China REGOTORI studies revealed that liver metastasis showed a poorer response to anti-PD-1 monotherapy than other metastases. The REGOTORI study also found that the intestinal flora may affect the efficacy of immunotherapy in MSS CRC [29]. In addition, tumor mutational burden (TMB) may be a biomarker for the response to immunotherapy. The CCTG CO.26 study showed that TMB is related to the efficacy of dual immunotherapy, and patients with TMB > 28 mts/Mb may benefit from immunotherapy [28]. These studies indicated that the discovery of novel biomarkers may widen the application of immunotherapy and bring new hope to CRC patients in the near future.

However, ICIs can cause a range of TRAEs affecting a multitude of organs, including skin, gastrointestinal tract, endocrine system, heart, lung, kidneys and the nervous system, and manageable safeties of anti-PD-1/PD-L1 were reported in various solid tumors, including melanoma, lung cancer, head and neck cancer, breast cancer, and urothelial carcinoma [40, 41]. Grades 3−5 TRAEs were observed in 33% of patients and 85% of patients had any grade of TRAEs. The most common AEs were diarrhea, fatigue, poor appetite, nausea, increased AST, rash, abdominal pain, fever, increased ALT, hypothyroidism and pancreatitis. This finding is roughly consistent with those of previous studies. However, it is worth noting that combination treatments might cause more TRAEs. Eng reported two of 179 patients treated with atezolizumab plus cobimetinib died of sepsis related to immune combination targeted therapy and one patient died of
sepsis in the study of Hellmann, using atezolizumab combined with cobimetinib in solid tumors.

This meta-analysis had several limitations. First, the 14 studies included were single-arm studies. Although there were two RCTs, only the outcome of ICIs-related groups were included in our meta-analysis because of different interventions. Therefore, the results could be affected. Second, although subgroup analyses were performed, the heterogeneity was not significantly decreased. Therefore, the results of this study should be interpreted with caution, and further large randomized clinical trials are needed for verification.

**Conclusion**

Despite the limitations of the included studies, the results of this meta-analysis indicated that immunotherapy has become an effective first-line treatment for patients with MSI-H/dMMR mCRC, and the combination of anti-PD-1/PD-L1 therapy with other therapies could be a useful strategy for the treatment of MSS/pMMR patients. The efficacy of immunotherapy was relatively low, underscoring the need to identify markers such as PD-L1 expression and different genotypes to predict the response to immunotherapy. High quality prospective studies and randomized controlled trials are needed to confirm these viewpoints.
Fig. 8  Forest plots of PD-L1 status of the ORR

Fig. 9  Publication bias of the overall ORR

Fig. 10  Publication bias of any grade adverse reaction
Acknowledgements
We thank all our authors listed in this manuscript.

Author contributions
All the authors contributed to manuscript writing, critical revision, and final review of the manuscript. YL, YD, ZZ and HX contributed to the conception, design of the study, and critical revision of the manuscript. YL and CX contributed to the data processing. PW, ND and GZ were responsible for the study selection, data extraction, and quality assessment. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
Materials described in the manuscript, including all relevant raw data, will be freely available to any researcher wishing to use them for non-commercial purposes. Please contact Dr. Zhu, the corresponding author, for any inquiries for the data.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author details
1 Department of Surgical Oncology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China. 2 Department of Surgical Oncology, The Fifth People’s Hospital of Shenyang City, Shenyang, China.

Received: 6 April 2022 Accepted: 16 September 2022 Published online: 10 October 2022

References
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLO-BOCAN estimates of incidence and mortality worldwide for 38 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
3. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26(21):3522–9.
4. Salz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):1913–9.
5. Hecht JR, Mitchell E, Chidic T, et al. A randomized phase IIIb trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27(5):672–80.
6. Yamazaki K, Nagase M, Tamagawa H, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016;27(8):1539–46.
7. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune check-point blockade therapy. Cancer Discov. 2018;8(9):1069–86.
8. Yaghoubi N, Soltani A, Ghazvini K, et al. PD-1/PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019;110:312–8.
9. Gong J, Chehrazi-Raffle A, Reddi S, et al. Development of PD-1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(11).
10. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.
11. Cohen EEW, Soulieres DJ, Tournade C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–67.
12. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.
13. Mvd D, Rischin D, Schmitts CD, et al. PD-1 blockade in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–51.
14. Andre T, Shiu KK, Kim TW, et al. Final overall survival for the phase III KN177 study: pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). J Clin Oncol. 2021;39(15_suppl):3500–3500.
15. Le DT, Uram JN, Wang H.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade %J Science. Science. 2017;357(6349):409.
16. Overman MJ, Lonardi S, Wong KY, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–9.
17. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91. https://doi.org/10.1016/S1470-2045(17)30422-9.
18. Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(11):11–9.
19. O’Neil BH, Wallmark JM, Lorente D, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS ONE. 2017;12(12): e0189848.
20. André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–18.
21. Fukuoka S, Haru H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONVO, EPOC1603). J Clin Oncol. 2020;38(18):10329.
22. Herting CJ, Farren MR, Tong Y, et al. A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. Cancer Immunol Immunother. 2021;70(11):3337–48.
23. Kawazoe A, Kuboki Y, Shinazaki E, et al. Multicenter phase II/I trial of napatupasibin and pembrolizumab in patients with metastatic colorectal cancer (EPOC 1503/SCOOP Trial). Clin Cancer Res. 2020;26(22):5887–94.
24. Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Falik M, Kozloff M, Segal NH, Sobrer A. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (MBLaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20(6):849–61.
25. Hellmann MD, Kim TW, Lee CB, et al. Phase I b study of atezolizumab combined with cobimetinib in patients with solid tumors. Ann Oncol. 2019;30(7):1134–42.

26. Parell MR, Falchook GS, Hamada K, et al. A phase 2 trial of trifluridine/ tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer. Cancer Med. 2021;10(4):1183–90.

27. Cousin S, Cantarel C, Guegan JP, et al. Regorafenib-Avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label. Phase II trial Clin Cancer Res. 2021;27(8):2139–47.

28. Chen EX, Jonker DJ, Loree JM, et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian cancer trials group CO26 study. JAMA Oncol. 2020;6(6):831–8.

29. Martinelli E, Martini G, Famiglietti V, et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type metastatic colorectal cancer: the phase 2 single-Arm clinical CAVÉ trial. JAMA Oncol. 2021;7(10):1529–35.

30. Wang F, He MM, Yao YC, et al. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/Ii clinical trial and gut microbiome analysis. Cell Rep Med. 2021;2(9):100383.

31. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

32. Buchroithner J, Pichler J, Marosi C, et al. Vascular endothelia growth factor targeted therapy may improve the effect of dendritic cell-based cancer immune therapy. Int J Clin Pharmacol Ther. 2014;52(1):76–7.

33. Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)—A proof of concept, open-label, nonrandomized phase Iia study. 2021, ASCO-GI. Abstract 80.

34. Martini G, Napolitano S, Famiglietti V, et al. Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: skin toxicity as a predictor of clinical activity. J Clin Oncol. 2021;39(15):3578.

35. Vital D, Ikenberg K, Moch H, et al. The expression of PD-L1 in salivary gland carcinomas. Sci Rep. 2019;9(1):12724.

36. Cao H, Wang Q, Gao Z, et al. Programmed death-ligand 1 and survival in colorectal cancers: a meta-analysis. Int J Biol Markers. 2019;34(4):356–63.

37. Valentini A, Di Pinto F, Cariola F, et al. PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. Oncotarget. 2018;9:8584–96.

38. El Jabbour T, Ross J, Sheehan C, et al. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. J Clin Pathol. 2018;71:46–51.

39. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6.

40. Chiem J, Htet Z, Zhao J, et al. Clinical presentation of immune-related endocrine adverse events during immune checkpoint inhibitor treatment. Cancers. 2022;14(11):2687. https://doi.org/10.3390/cancers14112687.

41. Wang B, Li F, Fan J, Lin G, Liu Q. Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: a systematic review and meta-analysis. Medicine. 2020;99: e21273.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.